Renalase deficiency aggravates ischemic myocardial damage

Kidney International

Volumn 79, Issue 8, 2011, Pages 853-860

  Wu, Yanling ^a,b   Xu, Jianchao ^a,b   Velazquez, Heino ^a,b   Wang, Peili ^a,b   Li, Guoyong ^a,b   Liu, Dinggang ^a   Sampaio Maia, Benedita ^c   Quelhas Santos, Janete ^c   Russell, Kerry ^a   Russell, Raymond ^a   Flavell, Richard A ^a   Pestana, Manuel ^c   Giordano, Frank ^a   Desir, Gary V ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VACHS Medical Center   (United States)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

amine oxidase; catecholamines; myocardial ischemia; NADH oxidase; renal failure; sympathetic nervous system

Indexed keywords

ALDOSTERONE; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOLAMINE; CREATININE; GLUTATHIONE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRATE; NITROGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; RENALASE; UNCLASSIFIED DRUG; UREA;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLUTATHIONE METABOLISM; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MOUSE; NITRATE METABOLISM; NONHUMAN; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

EID: 79953254377     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.488     Document Type: Article

References (33)

1. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295. (Pubitemid 39258422)
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
3. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004; 351: 1344-1346. (Pubitemid 39258430)
4. Coca SG, Peixoto AJ, Garg AX et al. The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis. Am J Kidney Dis 2007; 50: 712-720. (Pubitemid 47588552)
5. Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979. (Pubitemid 35176304)
6. Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14: 3239-3244. (Pubitemid 37509299)
7. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43: 699-706. (Pubitemid 38405571)
8. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004; 15: 524-537. (Pubitemid 38294782)
9. Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016. (Pubitemid 38251077)
10. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359. (Pubitemid 34260428)
11. Xu J, Li G, Wang P et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005; 115: 1275-1280. (Pubitemid 40629046)
12. Feng W, Nian-song W, Tao X et al. The cloning and expression of renalase and the preparation of its monoclonal antibody. J Shanghai Jiaotong Univ (Sci) 2009; 14: 376-379.
13. Li G, Xu J, Wang P et al. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation 2008; 117: 1277-1282. (Pubitemid 351365660)
14. Ghosh SS, Krieg RJ, Sica DA et al. Cardiac hypertrophy in neonatal nephrectomized rats: the role of the sympathetic nervous system. Pediatr Nephrol 2009; 24: 367-377.
15. Zhao Q, Fan Z, He J et al. Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population. J Mol Med 2007; 85: 877-885. (Pubitemid 47077106)
16. Lameris TW, de Zeeuw S, Alberts G et al. Time course and mechanism of myocardial catecholamine release during transient ischemia in vivo. Circulation 2000; 101: 2645-2650. (Pubitemid 30350645)
17. Edmondson DE, Binda C, Mattevi A. The FAD binding sites of human monoamine oxidases A and B. Neurotoxicology 2004; 25: 63-72. (Pubitemid 38044169)
18. Kwan SW, Lewis DA, Zhou BP et al. Characterization of a dinucleotidebinding site in monoamine oxidase B by site-directed mutagenesis. Arch Biochem Biophys 1995; 316: 385-391.
19. Schomig A, Dart A, Dietz R et al. Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A: Locally mediated release. Circ Res 1984; 55: 689-701. (Pubitemid 15176964)
20. Waldenstrom AP, Hjalmarson AC, Thornell L. A possible role of noradrenaline in the development of myocardial infarction: an experimental study in the isolated rat heart. Am Heart J 1978; 95: 43-51.
21. Cooper T, Willman VL, Jellinek M et al. Heart autotransplantation: effect on myocardial catecholamine and histamine. Science 1962; 138: 40-41.
22. Canto C, Gerhart-Hines Z, Feige JN et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458: 1056-1060.
23. Koch-Nolte F, Haag F, Guse AH et al. Emerging roles of NAD+ and its metabolites in cell signaling. Sci Signal 2009; 2: mr1.
24. Bruzzone S, Moreschi I, Guida L et al. Extracellular NAD+ regulates intracellular calcium levels and induces activation of human granulocytes. Biochem J 2006; 393: 697-704. (Pubitemid 43163809)
25. Moreschi I, Bruzzone S, Nicholas RA et al. Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes. J Biol Chem 2006; 281: 31419-31429. (Pubitemid 46041406)
26. Bruzzone S, Guida L, Zocchi E et al. Connexin 43 hemi channels mediate Ca2+-regulated transmembrane NAD+ fluxes in intact cells. FASEB J 2001; 15: 10-12.
27. Arcari P, Masullo L, Masullo M et al. A NAD(P)H oxidase isolated from the archaeon Sulfolobus solfataricus is not homologous with another NADH oxidase present in the same microorganism. Biochemical characterization of the enzyme and cloning of the encoding gene. J Biol Chem 2000; 275: 895-900. (Pubitemid 30051132)
28. Miramar MD, Costantini P, Ravagnan L et al. NADH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem 2001; 276: 16391-16398.
29. Chueh PJ, Morre DJ, Wilkinson FE et al. A 33.5-kDa heat- and proteaseresistant NADH oxidase inhibited by capsaicin from sera of cancer patients. Arch Biochem Biophys 1997; 342: 38-47. (Pubitemid 27217100)
30. Xu J, Li G, Wang P et al. Catecholamines regulate the activity, secretion and synthesis of renalase. Circulation 2008; 117: 1277-1282. (Pubitemid 351365660)
31. Park SY, Cho YR, Kim HJ et al. Unraveling the temporal pattern of dietinduced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 2005; 54: 3530-3540.
32. Soares-da-Silva P, Pestana M, Fernandes MH. Involvement of tubular sodium in the formation of dopamine in the human renal cortex. J Am Soc Nephrol 1993; 3: 1591-1599.
33. Russell III RR, Li J, Coven DL et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004; 114: 495-503. (Pubitemid 39572099)